Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
J Dermatolog Treat ; 32(2): 236-241, 2021 Mar.
Article in English | MEDLINE | ID: mdl-31403367

ABSTRACT

INTRODUCTION: Androgenetic alopecia is a stressful condition for males. Minoxidil 2% and 5% have been FDA approved for treatment of this condition. In literature, all studies have compared minoxidil 5% with 2%. Although other concentrations (2% to 12.5%) are available nowadays, we believe our study is the first to compare 10% versus 5% topical minoxidil in treatment of AGA. OBJECTIVE: To compare the efficacy and safety of 5% topical minoxidil with 10% topical minoxidil and placebo in AGA treatment. MATERIALS AND METHODS: 36-weeks, double-blinded, placebo-controlled, randomized trial. A total of 90 men with AGA. First group have applied 5% minoxidil solution, second group applied 10% minoxidil solution; or third placebo group. Efficacy was evaluated clinically and trichoscopically. RESULTS: After 36 weeks of therapy; 5% topical minoxidil (0.47 ± 0.26) (0.59 ± 0.64) was significantly superior to 10% topical minoxidil (0.05 ± 0.13) (0.45 ± 0.74) and placebo (0.01 ± 0.05) (-0.03 ± 0.08) in terms of change from baseline in total vertex and frontal hair mean count respectively. Pull test change to negative in minoxidil 5%: (37%) patients after 6 month treatment, Minoxidil 10% group (37.5%) patients changed and in placebo group all patients after 6 month were the same (0%) change. No reported sexual dysfunction in all three groups. CONCLUSION: Five percent of topical minoxidil was moderately superior to 10% topical minoxidil and placebo in increasing hair regrowth opposite to the expected, the irritation was marked for 10% topical minoxidil. Psychosocial stress after 10% usage were worsen by the shedding, irritation compared to their high expectation in comparison to 5% usage.


Subject(s)
Alopecia/drug therapy , Minoxidil/therapeutic use , Administration, Topical , Adult , Double-Blind Method , Hair/growth & development , Humans , Male , Patient Satisfaction , Placebo Effect , Treatment Outcome , Young Adult
2.
Opt Express ; 27(8): A352-A363, 2019 Apr 15.
Article in English | MEDLINE | ID: mdl-31052887

ABSTRACT

Photoelectrochemical water splitting is one of the viable approaches to produce clean hydrogen energy from water. Herein, we report MoS2/Si-heterojunction (HJ) photocathode for PEC H2 production. The MoS2/Si-HJ photocathode exhibits exceptional PEC H2 production performance with a maximum photocurrent density of 36.33 mA/cm2, open circuit potential of 0.5 V vs. RHE and achieves improved long-term stability up to 10 h of reaction time. The photocurrent density achieved by MoS2/Si-HJ photocathode is significantly higher than most of the MoS2 coupled Si-based photocathodes reported elsewhere, indicating excellent PEC H2 production performance.

SELECTION OF CITATIONS
SEARCH DETAIL
...